<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108377</url>
  </required_header>
  <id_info>
    <org_study_id>1406843</org_study_id>
    <nct_id>NCT04108377</nct_id>
  </id_info>
  <brief_title>Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma</brief_title>
  <official_title>Phosphodiesterase 4 Inhibitor, Roflumilast, Improves Beta Agonist Responsiveness Compared to Placebo in Low T2 Asthma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of roflumilast on restoring response β2 adrenoreceptor&#xD;
      agonists in low T2, obese asthmatics. One group of participants will receive roflumilast for&#xD;
      3 months, while the other will receive a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T2 low asthma is common in obese asthmatics. New evidence suggests that hyperinsulinemia and&#xD;
      insulin resistance, both common in obesity, are associated with an increased risk of&#xD;
      concurrent asthma.&#xD;
&#xD;
      Targeting Phosphodiesterase 4 inhibitors (PDE4) allows for examination of a mechanism&#xD;
      potentially linking obesity and asthma as well as identification of readily available and&#xD;
      safe options to treat hyperinsulinemic, overweight asthmatics.&#xD;
&#xD;
      It is hypothesized that obesity and hyperinsulinemia contribute to asthma by impairing β2&#xD;
      adrenoreceptor function and that this can be rescued the PDE4 inhibitor, roflumilast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Beta 2 Agonist response from Baseline</measure>
    <time_frame>3 months</time_frame>
    <description>Determine whether β2 receptor responsiveness is improved in response to albuterol in Group 1 (Roflumilast) patients compared to Group 2 (Placebo) patients at the study entry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>3 months</time_frame>
    <description>Determine where exhaled nitric oxide is lower in Group 1 vs Group 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test score</measure>
    <time_frame>3 months</time_frame>
    <description>The Asthma Control Test (TM © 2002 by QualityMetric) is a validated instrument to measure symptom control in asthma patients. There are 5 questions each with a score of 1-5 (25 total points). Poor asthma control is considered with a score less than 20 out of 25.&#xD;
Determine whether Asthma Control Test score is improved in Group 1 vs Group 2&#xD;
Asthma Control TestTM&#xD;
In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home?&#xD;
During the past 4 weeks, how often have you had shortness of breath?&#xD;
During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning?&#xD;
In the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)?&#xD;
How would you rate your asthma control during the past 4 weeks?</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast 500mcg by mouth, once daily, for 70 days (10 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth, once daily, for 70 days (10 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Roflumilast capsule</description>
    <arm_group_label>Roflumilast</arm_group_label>
    <other_name>Daliresp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic look of Roflumilast capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo for Roflumilast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a physician diagnosis of asthma.&#xD;
&#xD;
          -  Require treatment with moderate to high-dose &gt;2500mcg/day of fluticasone or&#xD;
             equivalent, or use of oral steroids&#xD;
&#xD;
        Also two of the following:&#xD;
&#xD;
          -  Requirement for additional daily treatment with other controller medication&#xD;
&#xD;
          -  Daily Asthma symptoms&#xD;
&#xD;
          -  Forced Expiratory Volume / Forced Vital Capacity (FEV1/FVC) &lt; 70% and FEV1&lt; 80%&#xD;
             predicted&#xD;
&#xD;
          -  ≥1 urgent care visits/year&#xD;
&#xD;
          -  ≥3 oral steroid bursts/year&#xD;
&#xD;
          -  Near-fatal asthma event.&#xD;
&#xD;
          -  Exhaled Nitric oxide (FeNO)&lt;30 ppb&#xD;
&#xD;
          -  Peripheral blood eosinophil count &lt; 300 (x10-6/ul)&#xD;
&#xD;
          -  Obesity, BMI≥30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  baseline FEV1 &lt;30% predicted&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  current smokers or subject with &gt;20 pack year history&#xD;
&#xD;
          -  any history of intolerance of, or reaction to, Roflumilast.&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Patients with liver disease&#xD;
&#xD;
          -  Subjects with Hepatic impairment (contraindicated in moderate-to-severe liver&#xD;
             impairment: Child-Pugh Score Class B/C) for example.&#xD;
&#xD;
          -  Patients with clinically significant psychiatric history (i.e., suicidality, etc.) and&#xD;
             psychiatric illness&#xD;
&#xD;
          -  Patients using strong CYP 450 enzyme inducers (e.g., rifampicin, phenobarbital,&#xD;
             carbamazepine, phenytoin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Kenyon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Kenyon, MD</last_name>
    <phone>530-754-6935</phone>
    <email>njkenyon@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Kenyon, MD</last_name>
      <phone>530-754-6935</phone>
      <email>njkenyon@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperinsulinemia</keyword>
  <keyword>Phosphodiesterase 4 Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

